PROGRAM CHAIRS
Timothy R. Aksamit, MD
Professor of Medicine
Consultant
Pulmonary Disease and Critical Care Medicine
Mayo Clinic
Rochester, MN
Pamela J. McShane, MD
Professor of Medicine
Division of Pulmonary and Critical Care
University of Texas Health Science Center at Tyler
Tyler, TX
PROGRAM OVERVIEW
This enduring activity will utilize audience response and game-playing technology to improve clinicians’ understanding of the pathophysiology of non-cystic fibrosis bronchiectasis (NCFB) so they can personalize patient treatments based on a therapy’s mechanism of action; diagnose NCFB earlier in the disease course; manage NCFB based on current clinical guidelines; and expand their knowledge of the safety and efficacy of approved and investigational drugs for this disease.
TARGET AUDIENCE
This activity is designed to meet the educational needs of US-based health care providers, clinicians, and researchers who have a role in the diagnosis and treatment of patients with non-CF bronchiectasis who work in pulmonology, respiratory, and primary care.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Analyze factors contributing to the pathophysiology of non-CF bronchiectasis to better understand the mechanism of action of emerging therapies that target neutrophil serine proteases
- Evaluate best practices in the diagnosis of non-CF bronchiectasis
- Summarize best practices in managing neutrophilic inflammation in non-CF bronchiectasis
- Discuss the results of clinical trials on approved and novel therapies for non-CF bronchiectasis that target neutrophil serine proteases
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in this enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this enduring activity for a maximum of 1.5 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Timothy R. Aksamit, MD | Dr. Aksamit discloses that he is the director of Bronchiectasis and NTM 360. He is involved with clinical studies with the US Bronchiectasis Research Registry, Bayer, Aradigm/Grifols, Gilead, Insmed, Zambon, AstraZeneca, Armata Pharmaceuticals, Spero Therapeutics, Electromed, Hillrom, and Respitech Medical. He receives no personal funding or research support. All funding goes to the Mayo Foundation for Medical Research and Education. |
| Pamela J. McShane, MD | Dr. McShane discloses that she is a consultant for Boehringer Ingelheim and Insmed. She also provides non-CME/CE services for Insmed. She is a Primary Investigator for AN2 Therapeutics, Armata Pharmaceuticals, Boehringer Ingelheim, Electromed, Insmed, MannKind, Paratek, Renovion, Sanofi, and Spero Therapeutics. She is on the Advisory Board for Boehringer Ingelheim, Insmed, and Sanofi. |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Mike Milano, MD, discloses that he has received royalties from Wolters Kluwer (UpToDate author royalties).
- Shannon Mutch, MS, RN, OCN, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Deb Gordon, MS, Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Lisa Crenshaw, Program Director for Med Learning Group, has nothing to disclose.
- Daniel DaSilva, Accreditation and Outcomes Coordinator, for Med Learning Group, has nothing to disclose.
- Jacquelyn Sandfort, Program Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: November 08, 2024
EXPIRATION DATE: November 08, 2025
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
